NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value
The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains over 180 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading antibiotics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2007.
In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.
Antibiotics Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of antibiotic deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibiotics agreements with numerous real life case studies
Comprehensive access to over 160 actual antibiotics contracts entered into by the world's biopharma companies
Detailed access to actual antibiotics contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a antibiotics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.
Antibiotics Partnering Terms and Agreements includes:
Trends in antibiotics dealmaking in the biopharma industry since 2007
Analysis of antibiotics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibiotics deals
Access to over 180 antibiotics contract documents
The leading antibody deals by value since 2007
Most active antibiotics dealmakers since 2007
The leading antibiotics partnering resources
In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:
Stage of development at signing
Deal component type
Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
TABLE OF CONTENTS
Chapter 1 – Introduction
Chapter 2 – Trends in antibiotics dealmaking
2.2. Antibiotics partnering over the years
2.3. Bigpharma antibiotics dealmaking activity
2.4. Most active in antibiotics partnering
2.5. Antibiotics partnering by deal type
2.5. Antibiotics partnering by disease type
2.6. Partnering by antibiotics technology type
2.7. Average deal terms for antibiotics partnering
2.7.1 Antibiotics headline values
2.7.2 Antibiotics upfront payments
2.7.3 Antibiotics milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of antibiotics partnering
2.9. The anatomy of antibiotics deal
2.9.a. Case study 1: Calixa Therapeutics & Astellas –May 24 2009
2.9.b. Case study 2: Advanced Life Sciences & Wyeth- Oct 1 2008
2.9.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011
Chapter 3 – Leading antibiotics deals
3.2. Top antibiotics deals by value
Chapter 4 – Bigpharma antibiotics deals
4.2. How to use bigpharma antibiotics partnering deals
4.3. Big pharma antibiotics partnering company profiles
Actavis Inc (formerly Watson Pharmaceuticals)
Merck & Co
Chapter 5 – Antibiotics partnering contracts directory
5.2. Company A-Z
Advanced Life Sciences
Advanced Technology Company
Albany Molecular Research
Almac Pharma Services
Beth Israel Deaconess Medical Center
Biomedical Advanced Research and Development Authority
Brigham and Women's Hospital
Center for Disease Control and Prevention
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Therapeutics
Defense Threat Reduction Agency
Department of Defense
Department of Health and Human Services
Dow Pharmaceutical Sciences
Families of Spinal Muscular Atrophy
Flemish agency for Innovation by Science and Technology
Food and Drug Administration (FDA)
France's General Directorate for Armaments
Innovative Medicines Initiative (IMI)
Institute of Materia Medica
Inverness Medical Innovations
Johnson & Johnson
Lawrence Livermore National Laboratory
Medical Research Council
Merck & Co
Merus Labs International
National Heart, Lung and Blood Institute
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Novartis Institute for Tropical Diseases
Orchid Chemicals and Pharma
PATH (Appropriate Technology in Health)
Research Council of Norway
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Shanglian Biochemical Medicine
Sichuan Jiangchuan Pharmaceutical
Sichuan Mingxin Pharmaceutical
Statens Serum Institute
Swedish Orphan Biovitrum
Swedish University of Agricultural Sciences
TransPerfect Trial Interactive
University of North Carolina
US Army Medical Research Institute of Infectious Diseases
Walter Reed Army Institute of Research
Yissum Research Development
5.3. By deal type
Manufacturing - OEM
5.4. By stage of development
5.5. By therapy area
Central Nervous System
Chapter 6 – Antibiotics dealmaking by technology type
6.2. Deals by antibiotics type
Appendix – Antibiotics partnering resource center
Online antibiotics partnering
Antibiotics partnering events
Further reading on antibiotics dealmaking
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures
Figure 1: Antibiotics partnering since 2007
Figure 2: Bigpharma – top 50 – antibiotics deals 2007 to 2013
Figure 3: Bigpharma antibiotics deal frequency – 2007 to 2013
Figure 4: Active antibiotics dealmaking activity– 2007 to 2013
Figure 5: Antibiotics partnering by deal type since 2007
Figure 7: Antibiotics partnering by disease type since 2007
Figure 9: Antibiotics partnering by technology type since 2007
Figure 8: Antibiotics deals with a headline value
Figure 9: Antibiotics deal headline value distribution, US$million – discovery stage
Figure 10: Antibiotics deal headline value distribution, US$million – preclinical stage
Figure 11: Antibiotics deal headline value distribution, US$million – phase I stage
Figure 12: Antibiotics deal headline value distribution, US$million – phase II stage
Figure 13: Antibiotics deal headline value distribution, US$million – phase III stage
Figure 14: Antibiotics deal headline value distribution, US$million – regulatory stage
Figure 15: Antibiotics deal headline value distribution, US$million – marketed stage
Figure 16: Summary median headline value by stage of development, 2007-2013
Figure 17: Antibiotics deals with upfront payment values
Figure 18: Antibiotics deal upfront payment distribution, US$million – discovery stage
Figure 19: Antibiotics deal upfront payment distribution, US$million – preclinical stage
Figure 20: Antibiotics deal upfront payment distribution, US$million – phase I stage
Figure 21: Antibiotics deal upfront payment distribution, US$million – phase II stage
Figure 22: Antibiotics deal upfront payment distribution, US$million – phase III stage
Figure 23: Antibiotics deal upfront payment distribution, US$million – regulatory stage
Figure 24: Antibiotics deal upfront payment distribution, US$million – marketed stage
Figure 25: Summary median upfront payments by stage of development, 2007-2013
Figure 26: Antibiotics deals with milestone payments
Figure 27: Antibiotics deal milestone distribution, US$million – discovery stage
Figure 28: Antibiotics deal milestone distribution, US$million – preclinical stage
Figure 29: Antibiotics deal milestone distribution, US$million – phase I stage
Figure 30: Antibiotics deal milestone distribution, US$million – phase II stage
Figure 31: Antibiotics deal milestone distribution, US$million – phase III stage
Figure 32: Antibiotics deal milestone distribution, US$million – regulatory stage
Figure 33: Antibiotics deal milestone distribution, US$million – marketed stage
Figure 34: Antibiotics deals with royalty rates, %
Figure 35: Antibiotics deal royalty rate distribution, US$million – discovery stage
Figure 36: Antibiotics deal royalty rate distribution, US$million – preclinical stage
Figure 37: Antibiotics deal royalty rate distribution, US$million – phase I stage
Figure 38: Antibiotics deal royalty rate distribution, US$million – phase II stage
Figure 39: Antibiotics deal royalty rate distribution, US$million – phase III stage
Figure 40: Antibiotics deal royalty rate distribution, US$million – regulatory stage
Figure 41: Antibiotics deal royalty rate distribution, US$million – marketed stage
Figure 42: Summary median royalty rate by stage of development, 2007-2013
Figure 43: Components of the typical antibiotics deal structure
Figure 44: Top antibiotics deals by value since 2007
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events
Janssen Research & Development
La Jolla Pharmaceutical
Merck and Co
Merck Sharpe & Dohme
Novartis Consumer Health
Procter & Gamble
Procter & Gamble Pharmaceuticals
To order this report: Antibiotics Partnering Terms and Agreements
Contact Clare: email@example.com
Intl: +1 339-368-6001
- Health Care Industry
- Pharmaceuticals & Drug Trials